{
  "asset": {
    "name": "KT-485",
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "target": {
      "name": "IRAK4",
      "full_name": "Interleukin 1 Receptor Associated Kinase 4",
      "pathway": "IL-1R/TLR signaling pathway",
      "biology": "IRAK4 is an obligate node in IL-1R/TLR signaling with both scaffolding and kinase functions. Master regulator of innate immunity controlling Th1/Th2/Th17 inflammation and cytokines IL-1, IL-18, IL-33, IL-36",
      "genetic_validation": "Adult humans with IRAK4 null mutation are healthy, demonstrating safety of target",
      "why_undruggable_before": "Scaffolding function requires complete pathway blockade, which degradation uniquely achieves vs inhibition"
    },
    "mechanism": {
      "type": "Protein degrader",
      "description": "Degradation is the only approach to fully block the IL-1R/TLR pathway and achieve combined activity of upstream biologics (anti-IL-1/18/33/36) in oral form",
      "differentiation": "Second generation degrader with increased selectivity and potency over KT-474, no QTc signal"
    },
    "modality": "Small molecule degrader",
    "ownership": "Partnered with Sanofi"
  },
  "clinical_development": {
    "current_stage": "Phase 1 (planned)",
    "lead_indication": "Hidradenitis Suppurativa",
    "expansion_indications": [
      "Atopic Dermatitis",
      "Asthma",
      "COPD",
      "Rheumatoid Arthritis",
      "Systemic Lupus Erythematosus",
      "Ulcerative Colitis",
      "Crohn's Disease"
    ]
  },
  "market_opportunity": {
    "tam": ">$55B in combined global drug sales opportunity",
    "patient_population": ">140M patients",
    "current_treatment": "Injectable biologics targeting individual cytokines",
    "unmet_need": "Only ~3% of patients have access to systemic advanced therapies"
  },
  "trials": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    51,
    64
  ],
  "_last_extracted": "2026-02-04T13:46:43.246794"
}